Abstract
| Original language | English |
|---|---|
| Article number | e12731 |
| Pages (from-to) | (In-Press) |
| Number of pages | 9 |
| Journal | Clinical Obesity |
| Volume | 15 |
| Issue number | 3 |
| Early online date | 19 Jan 2025 |
| DOIs | |
| Publication status | Published - Jun 2025 |
Bibliographical note
© 2025 The Author(s). Clinical Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Funder
ME and PI have no conflicts of interest. NI declares being a trustee of the Obesity Empowerment Network and an active patient advocate. BS declares being an active patient advocate. PS has no conflicts of interest. SA declares research support from Johnson & Johnson as well as the British Dietetic Association as well as consulting fees from AstraZeneca and Johnson & Johnson and ICE creates as well as support for attending educational meetings from Novo Nordisk and the British Dietetic Association as well as committee-level membership of British Obesity and Metabolic Surgery Society and British Dietetic Association Obesity Specialist Group and Obesity Management Collaborative, UK. TW has no conflicts of interest. KN declares grants from NIHR, UKRI/MRC, Kennedy Trust for Rheumatology Research, Health Data Research UK, Wellcome Trust, European Regional Development Fund, Institute for Global Innovation, Boehringer Ingelheim, Action Against Macular Degeneration Charity, Midlands Neuroscience Teaching and Development Funds, South Asian Health Foundation, Vifor Pharma, College of Police, and CSL Behring as well as consultancy fees from BI, Sanofi, CEGEDIM and MSD and leadership roles within NICST, a charity and OpenClinical, a Social Enterprise. SB declares speaker fees and AstraZeneca, Boehringer Ingelheim, NovoNordisk and Eli Lilly and received research funds from AstraZeneca and Bayer. SWF declares grants from NIHR, Office of Health Improvement and Disparities, Doncaster Council and Novo Nordisk as well as support for attendance at meetings or travel from UK Parliament, Johnson and Johnson, Novo Nordisk, Devon NHS Integrate Care Service and Safefood. DJP declares consulting fees from Johnson & Johnson, Novo Nordisk, Pfizer, GSK, and Medtronic as well as honoraria from Johnson & Johnson, Medtronic, Sandoz and Novo Nordisk. JMH declares grant funding from NIHR and previous advisory feed and speaking honoraria from Novo Nordisk as well as support for attendance at meetings from Novo Nordisk and Eli Lilly as well as being a committee member of Obesity Management Collaborative UK.Funding
ME and PI have no conflicts of interest. NI declares being a trustee of the Obesity Empowerment Network and an active patient advocate. BS declares being an active patient advocate. PS has no conflicts of interest. SA declares research support from Johnson & Johnson as well as the British Dietetic Association as well as consulting fees from AstraZeneca and Johnson & Johnson and ICE creates as well as support for attending educational meetings from Novo Nordisk and the British Dietetic Association as well as committee-level membership of British Obesity and Metabolic Surgery Society and British Dietetic Association Obesity Specialist Group and Obesity Management Collaborative, UK. TW has no conflicts of interest. KN declares grants from NIHR, UKRI/MRC, Kennedy Trust for Rheumatology Research, Health Data Research UK, Wellcome Trust, European Regional Development Fund, Institute for Global Innovation, Boehringer Ingelheim, Action Against Macular Degeneration Charity, Midlands Neuroscience Teaching and Development Funds, South Asian Health Foundation, Vifor Pharma, College of Police, and CSL Behring as well as consultancy fees from BI, Sanofi, CEGEDIM and MSD and leadership roles within NICST, a charity and OpenClinical, a Social Enterprise. SB declares speaker fees and AstraZeneca, Boehringer Ingelheim, NovoNordisk and Eli Lilly and received research funds from AstraZeneca and Bayer. SWF declares grants from NIHR, Office of Health Improvement and Disparities, Doncaster Council and Novo Nordisk as well as support for attendance at meetings or travel from UK Parliament, Johnson and Johnson, Novo Nordisk, Devon NHS Integrate Care Service and Safefood. DJP declares consulting fees from Johnson & Johnson, Novo Nordisk, Pfizer, GSK, and Medtronic as well as honoraria from Johnson & Johnson, Medtronic, Sandoz and Novo Nordisk. JMH declares grant funding from NIHR and previous advisory feed and speaking honoraria from Novo Nordisk as well as support for attendance at meetings from Novo Nordisk and Eli Lilly as well as being a committee member of Obesity Management Collaborative UK.
Keywords
- bariatric surgery
- commissioning
- obesity
- specialist weight management
- tier 3
- tier 4
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism